Scholarlink

Background <p>Human cytomegalovirus (HCMV) infection is implicated in glioblastoma pathogenesis through oncogenic and immunomodulatory mechanisms; however, prevalence estimates remain highly variable across studies, warranting systematic evaluation.</p> Methods <p>We systematically searched PubMed, Embase, LILACS, SciELO, and Cochrane for studies on HCMV detection in patients with glioblastoma. A single-arm meta-analysis estimated pooled prevalence with subgroup analyses by region, country, income level, antibody, and detection method. Random-effects models (95% CI) were applied, and heterogeneity quantified using I².</p> Results <p>19 studies comprising 988 glioblastoma patients were included, HCMV positivity was 68% (95% CI, 0.53 to 0.80; <i>P</i> &lt; 0.0001; I² = 91.4%). Subgroup analyses revealed a significant prevalence in Europe and Central Asia (82%; 95% CI, 0.38 to 0.97; <i>P</i> &lt; 0.0001; I² = 94.7%) and North America (78%; 95% CI, 0.23 to 0.98; <i>P</i> &lt; 0.0001; I² = 94.3%), followed by Middle East/North Africa (72%; 95% CI, 0.45 to 0.89; <i>P</i> &lt; 0.0001; I² = 87.4%), Latin America and Caribbean (65%; 95% CI, 0.25 to 0.91; <i>P</i> &lt; 0.0001; I² = 85.5%), and East Asia and Pacific (51%; 95% CI, 0.16 to 0.86; <i>P</i> &lt; 0.0001; I² = 94.6%). High-income and upper-middle-income countries have a predominance of 69% and 73% (95% CI, 0.40 to 0.88 and 0.52 to 0.87, <i>P</i> &lt; 0.0001, I² = 95.2% and 83.5%) compared to lower-middle-income (53%; 95% CI, 0.25 to 0.79; <i>P</i> = 0.0012; I² = 90.4%). Technique methods influenced prevalence, with IHC showing 74% positivity versus 66% with PCR, and 65% with ELISA. Antibody analysis highlighted the significance of UL83 (95%) and IE-72 (87%) within studies.</p> Conclusion <p>This meta-analysis revealed high HCMV detection in patients with glioblastoma, although results varied by region, income, technique, and antibody. Standardized protocols and large studies are needed to clarify HCMV’s role and implications for targeted therapies.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence of human cytomegalovirus in glioblastoma multiforme: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年12月29日

查看全文
  • Francisco Cezar Aquino de Moraes,
  • Pedro Bartkevitch Rodrigues,
  • Lucas David de Souza Vital,
  • Barbara Antonia Dups Talah,
  • Rommel Mario Rodríguez Burbano,
  • Mario Hiroyuki Hirata

摘要

Background

Human cytomegalovirus (HCMV) infection is implicated in glioblastoma pathogenesis through oncogenic and immunomodulatory mechanisms; however, prevalence estimates remain highly variable across studies, warranting systematic evaluation.

Methods

We systematically searched PubMed, Embase, LILACS, SciELO, and Cochrane for studies on HCMV detection in patients with glioblastoma. A single-arm meta-analysis estimated pooled prevalence with subgroup analyses by region, country, income level, antibody, and detection method. Random-effects models (95% CI) were applied, and heterogeneity quantified using I².

Results

19 studies comprising 988 glioblastoma patients were included, HCMV positivity was 68% (95% CI, 0.53 to 0.80; P < 0.0001; I² = 91.4%). Subgroup analyses revealed a significant prevalence in Europe and Central Asia (82%; 95% CI, 0.38 to 0.97; P < 0.0001; I² = 94.7%) and North America (78%; 95% CI, 0.23 to 0.98; P < 0.0001; I² = 94.3%), followed by Middle East/North Africa (72%; 95% CI, 0.45 to 0.89; P < 0.0001; I² = 87.4%), Latin America and Caribbean (65%; 95% CI, 0.25 to 0.91; P < 0.0001; I² = 85.5%), and East Asia and Pacific (51%; 95% CI, 0.16 to 0.86; P < 0.0001; I² = 94.6%). High-income and upper-middle-income countries have a predominance of 69% and 73% (95% CI, 0.40 to 0.88 and 0.52 to 0.87, P < 0.0001, I² = 95.2% and 83.5%) compared to lower-middle-income (53%; 95% CI, 0.25 to 0.79; P = 0.0012; I² = 90.4%). Technique methods influenced prevalence, with IHC showing 74% positivity versus 66% with PCR, and 65% with ELISA. Antibody analysis highlighted the significance of UL83 (95%) and IE-72 (87%) within studies.

Conclusion

This meta-analysis revealed high HCMV detection in patients with glioblastoma, although results varied by region, income, technique, and antibody. Standardized protocols and large studies are needed to clarify HCMV’s role and implications for targeted therapies.

Graphical Abstract